Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jeffrey S, Sklar"'
Autor:
Joseph P, Eder, Deborah B, Doroshow, Khanh T, Do, Vicki L, Keedy, Jeffrey S, Sklar, Peter, Glazer, Ranjit, Bindra, Geoffrey I, Shapiro
Publikováno v:
JCO precision oncology. 5
Tumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting in sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combination trial is a phase II, open-label study in which patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::177ac35c3f2f6ef8561450493e8b755e
https://pubmed.ncbi.nlm.nih.gov/35675574
https://pubmed.ncbi.nlm.nih.gov/35675574
Autor:
Jeffrey S. Sklar, Deborah B. Doroshow, Peter M. Glazer, Vicki L. Keedy, Khanh T. Do, Joseph Paul Eder, Geoffrey I. Shapiro, Ranjit Bindra
Publikováno v:
JCO Precis Oncol
PURPOSE Tumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting in sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combination trial is a phase II, open-label study in which pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d691a50672162c42b9e5c237c257c7
https://europepmc.org/articles/PMC9848565/
https://europepmc.org/articles/PMC9848565/
